Plus Therapeutics is pleased to announce that its abstract has been accepted for a Poster Spotlight with Oral Presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS 2025), taking place December 9–12, 2025, in San Antonio, Texas.
This recognition underscores the growing scientific interest in the Company’s work to advance innovative radiotherapeutic options for patients with leptomeningeal metastases (LM) originating from breast cancer and other solid tumors.
Read the full press release: https://lnkd.in/g26yc87k
Highlighting New Research in Leptomeningeal Metastases
Leptomeningeal metastases represent one of the most serious and complex complications of metastatic breast cancer. With limited treatment options and poor prognosis, LM remains a major unmet medical need in oncology.
The accepted abstract will feature new data supporting Plus Therapeutics’ development of REYOBIQ™, the Company’s targeted radiotherapeutic engineered for delivery directly into the cerebrospinal fluid (CSF). This approach aims to provide safer, more precise, and more effective treatment for patients with LM, who often struggle to access therapies that can penetrate the central nervous system.
Researchers from UT Health San Antonio, long-standing clinical partners in the ReSPECT-LM trial, will join in presenting the findings at SABCS 2025.
Advancing Clinical Development Through the ReSPECT-LM Trial
Plus Therapeutics continues to progress the ReSPECT-LM clinical trial, designed to evaluate the safety and efficacy of REYOBIQ for patients with LM from breast cancer and other malignancies.
The upcoming SABCS Spotlight presentation will provide important insights into the therapy’s clinical trajectory and the Company’s broader vision for improving outcomes in CNS metastatic disease.
A Meaningful Opportunity at SABCS 2025
SABCS is one of the most influential breast cancer research meetings globally, bringing together oncologists, researchers, and industry leaders to discuss emerging science and therapeutic innovation. Being selected for a Spotlight with Oral Presentation reflects the significance of Plus Therapeutics’ clinical research and its potential impact on patient care.
As the Company continues to advance its radiotherapeutic programs, more data and milestones are expected to be shared in the months ahead.
Recent Comments